title: The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial.
abstract: OBJECTIVE
  To provide preliminary evidence on the effectiveness and optimal dosage of megestrol acetate for older persons with impaired appetite after hospitalization.
  
  
  METHODS
  Randomized clinical trial.
  
  
  METHODS
  Acute care hospital.
  
  
  METHODS
  Forty-seven older persons (mean age 83) who were recently discharged from an acute care hospital and had fair or poor appetite.
  
  
  METHODS
  Participants were randomized to placebo or megestrol acetate suspension 200 mg, 400 mg, or 800 mg daily for 9 weeks.
  
  
  METHODS
  Appetite, health-related quality of life, and adverse effects were measured at baseline and 20, 42, and 63 days. Serum nutritional markers were measured at baseline and 20 and 63 days.
  
  
  RESULTS
  During the course of the study, there were no significant differences between treatment groups on any of the appetite questions, although participants in the 400-mg and 800-mg groups demonstrated significant improvement from baseline on some questions. At 20 days, prealbumin increased in a dose-response relationship across the four groups (by 0.4, 5.1, 7.5, and 9.0 mg/dL, respectively). Participants in the 400-mg and 800-mg groups demonstrated greater improvement in prealbumin levels at 20 days than those receiving placebo (P=.009 and P=.004, respectively) and those in the 400-mg group also demonstrated improvement at 63 days (P=.02). At 20 days, no participant taking placebo had a morning serum cortisol level less than 8 ng/mL (the lower limit of normal). In contrast, 33%, 70%, and 78% of those taking 200 mg, 400 mg and 800 mg, respectively, had values below this level; by 63 days, these percentages were 11%, 30%, 56%, and 37%, respectively. No patient reported clinical symptoms of adrenal insufficiency. Diarrhea developed in three subjects, and thromboembolism occurred in two receiving active treatment.
  
  
  CONCLUSIONS
  Megestrol acetate at doses of 400 mg and 800 mg increases prealbumin in recently hospitalized older persons. Cortisol suppression is common at higher doses and may be persistent. In this small study, the drug did not confer benefit on other nutritional or clinical outcomes.
authors.affiliation: UCLA Multicampus Program in Geriatric Medicine and Gerontology, University of California at Los Angeles, Los Angeles, California 90095, USA. dreuben@mednet.ucla.edu
authors.forename: David B
authors.initials: DB
authors.lastname: Reuben
authors.forename: Susan H
authors.initials: SH
authors.lastname: Hirsch
authors.forename: Kefei
authors.initials: K
authors.lastname: Zhou
authors.forename: Gail A
authors.initials: GA
authors.lastname: Greendale
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D001066:Appetite / Q000187:drug effects*; D019167:Appetite Stimulants / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D001068:Feeding and Eating Disorders / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006760:Hospitalization; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D019290:Megestrol Acetate / Q000008:administration & dosage*; D015596:Nutrition Assessment; D012709:Serum Albumin / Q000032:analysis; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D019167:Appetite Stimulants; D012709:Serum Albumin; D013535:Suspensions; D019290:Megestrol Acetate; D006854:Hydrocortisone